Study Details: Hydroxychloroquine to Enhance Doxorubicin Effectiveness
Tumor: any measurable cancer disease
Purpose of study: This clinical trial is designed to evaluate a form of treatment for dogs with cancer using a combination of the antimalarial drug hydroxychloroquine (HCQ) and the chemotherapy agent doxorubicin (DOX). Recent studies suggest that HCQ can sensitize human tumor cells to the anti-cancer effect of DOX. Recent studies in dogs with skin disease have demonstrated that long-term HCQ treatment appears to be well-tolerated. The combination of these two treatments has not been explored in canine cancer patients. The goal of this study is to determine the maximum tolerated dose of HCQ that can be administered to tumor-bearing dogs when followed by a standard dose of DOX. For more information, click here.